This inventor holds 1 USPTO granted patent. Top assignee: Seoul National University. Active years: 2023.
Company Filing History:
Years Active: 2023
Title: Innovator Won-Ick Chang: Advancing Cancer Treatment Through Innovative Patents
Introduction
Won-Ick Chang, a prominent inventor based in Seoul, South Korea, has made significant strides in the field of medical innovation. With a focus on developing advanced treatment methods for breast cancer, his work is representative of the ongoing efforts to enhance therapeutic efficacy and improve patient outcomes.
Latest Patents
Chang's most notable patent, titled "Method of treating metastatic triple negative breast cancer with radiotherapy combined with phosphatidyl inositol-3 kinase delta/gamma inhibitors and anti-PD-1 antibodies," addresses a critical area in cancer treatment. This invention proposes a pharmaceutical composition designed to work in conjunction with radiotherapy, specifically targeting triple negative breast cancer. The innovative approach combines a PD-1 blockade with PI3Kδ/γ inhibitors, demonstrating superior effects in tumor inhibition and immune enhancement compared to standalone therapies.
Career Highlights
Currently affiliated with the Seoul National University R&DB Foundation, Won-Ick Chang's professional journey is marked by his commitment to cancer research and treatment innovations. His work integrates pharmacology with radiotherapy, contributing essential knowledge to the medical community and paving the way for new treatment protocols.
Collaborations
During his career, Chang has collaborated with esteemed colleagues, including In-Ah Kim and Min-Guk Han. Their joint efforts emphasize the importance of interdisciplinary collaboration in research and development, showcasing how diverse expertise can drive significant advancements in healthcare.
Conclusion
Won-Ick Chang's contributions to medical science, particularly in the realm of oncology, highlight the importance of innovation in developing effective treatment strategies. His patent not only represents a potential breakthrough in the management of metastatic triple negative breast cancer but also serves as an inspiration for future research and development in the field. With ongoing advancements in medical technology and collaborative efforts among researchers, the fight against cancer continues to evolve.